Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | AKT2 | P31751 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 9/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 3/20 | 0.38 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2965523 | 0.91 | PIM1 (0.55) | PIM1AKT2MAOBACHEMAOA | |
| SCHEMBL2961613 | 0.91 | PIM1 (0.60) | PIM1AKT2MAOBACHEMAOA | |
| SCHEMBL2964540 | 0.90 | PIM1 (0.54) | PIM1AKT2MAOBACHEMAOA | |
| SCHEMBL2963629 | 0.90 | PIM1 (0.58) | PIM1AKT2MAOBMAOA | |
| SCHEMBL2970350 | 0.90 | PIM1 (0.45) | PIM1AKT2MAOBACHEMAOA | |
| SCHEMBL2960446 | 0.89 | PIM1 (0.41) | PIM1AKT2MAOBACHEMAOA | |
| SCHEMBL809927 | 0.88 | PIM1 (0.71) | PIM1AKT2MAOBACHEMAOA | |
| SCHEMBL2954780 | 0.86 | PIM1 (0.59) | PIM1AKT2MAOBACHEMAOA | |
| SCHEMBL2969828 | 0.86 | PIM1 (0.55) | PIM1AKT2MAOBACHEMAOA | |
| SCHEMBL2971513 | 0.85 | PIM1 (0.54) | PIM1AKT2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338605-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100256139-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-10-07 | — | — | US | disclosed |
| EP-1979349-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2010-07-28 | — | — | EP | disclosed |
| US-7763731-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | PIM1 2963/4885AKT2 3903/4885MAOB 3352/4885 |
| US-20100256139-A1 | Anti-Viral Compounds | HAVCR2, MAVS, EIF2AK2 | PIM1 2963/4885AKT2 3903/4885MAOB 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.